University of Washington
The work in the Sherman lab is focused on understanding how M. tuberculosis senses and responds to stresses, such as the immune system or drugs, with the goal of contributing to the development of novel and effective therapeutic and diagnostic regimens.
David R. Sherman
Professor and Chair
Department of Microbiology, University of Washington School of Medicine
Dr. Sherman is a microbiologist with a background in molecular genetics and biochemistry and is Chair of the Department of Microbiology, University of Washington School of Medicine. For years, he has studied the regulation of bacterial gene expression, particularly as it relates to TB latency, pathogenesis and drug response. In addition to his role as Project 4 Lead Investigator on this proposal, he is co-investigator on the current CLEAR-TB (TBRU) U19, and co-PI of U19 AI135976, Omics for TB: Response to Infection and Treatment, which offers many opportunities for synergy with CLEAR-TB. He Is also co-PI of the Seattle TB Research Administrave Center, SEATRAC (1P30AI168034-01).
Dr. Sherman is the Lead Investigator on Project 4 – Drug tolerance, bacterial heterogeneity and adverse TB treatment outcomes
Mark Jones
Acting Instructor
Department of Microbiology, University of Washington School of Medicine
Dr. Jones previously earned his PhD from the University of Georgia and trained as a postdoc at the Johns Hopkins Bloomberg School of Public Health. His microbial pursuits have been centered around the exploration of host-microbe interactions, working with the squid-Vibrio model system, enteric pathogens, and now mycobacterial infection. In the Sherman lab, he is interested in uncovering how Mtb survives in caseous lesions – a critical hurdle in the development of new therapeutic and diagnostic regimens.
Hassan Eldesouky
Postdoctoral Associate
Department of Microbiology, University of Washington School of Medicine
Hassan Eldesouky is a postdoctoral researcher in Sherman’s lab. Hassan has a pharmacy degree from Egypt and a Ph.D. from Purdue University. His main research interest focuses on utilizing combinatorial therapeutics to target clinically important phenotypes such as drug resistance and persistence. Being intrigued by the promiscuous nature of the small chemical molecules and their astonishing ability to produce multiple off-target effects, Hassan is trying to harness this phenomenon to define novel mechanisms of persistence in Mycobacterium tuberculosis and to identify novel drug targets.